Investors ding Tesaro despite responses for combo in NSCLC

Tesaro Inc. (NASDAQ:TSRO) reported data Friday from the Phase I AMBER trial showing that a combination of TSR-022 and TSR-042 led to four confirmed partial responses and 11 cases of stable disease among 31 evaluable non-small cell lung cancer patients who progressed following anti-PD-1 treatment.